Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2011

View Archived Issues

Histamine H3 receptor antagonist JNJ-39220675 shows promise against alcoholism

Resminostat advances in phase I/II SHORE trial in colorectal cancer

BioMarin begins phase I/II trial of BMN-701 in late-onset Pompe's disease

Chinese scientists develop polycaprolactone-magnesium scaffold for bone repair

Masitinib mesilate prolongs survival of imatinib-naive subjects with advanced/metastatic GIST

Xybrex has analgesic activity in subjects undergoing iliac crest bone graft harvesting

Scientists identify satellite repeats in heterochromatin that are overexpressed in epithelial cancer

MycoVa demonstrates noninferiority to Loceryl in onychomycosis

Transcept resubmits Intermezzo NDA for insomnia to FDA

New activators of pyruvate kinase isozymes M1/M2 claimed

AstraZeneca presents new beta-secretase 1 inhibitors

Auspex Pharma patents new beta3-adrenoceptor modulators

New glucocorticoid receptor agonists discovered

FDA and Health Canada grant telaprevir priority review for HCV infection

Amicus Therapeutics announces milestones expected for 2011

Evotec and Takeda Cambridge join to identify GPCR and protease modulators

Geron begins phase II trial of imetelstat in essential thrombocythemia

Theraclone and Pfizer to codevelop antibodies against infectious disease and cancer targets

FDA sets PDUFA date for Adventrx's Exelbine NDA

NerBloc approved in Japan for treatment of cervical dystonia

CHMP issues positive opinion on European orphan drug status for darinaparsin in PTCL

Phase III data reported on levomilnacipran in major depressive disorder

New osteoporosis drug Edirol approved in Japan

Daiichi Sankyo's Alzheimer's disease treatment Memary approved in Japan

Health Canada approves once-daily antidepressant Oleptro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...